银屑病按需生物制剂治疗的可接受性:多利益相关方混合方法研究
该混合方法研究通过英国全国范围在线调查和定性焦点小组,探讨患者和皮肤科医生对银屑病按需生物制剂治疗的可接受性。调查中67%患者和78%临床医生支持该策略,焦点小组认为可减少治疗负担并促进患者自主管理,但需关注复发风险和药物可及性。结论认为按需生物制剂治疗对患者和医生均可接受,需进一步评估临床效果和成本效益。
要点
- 67%患者和78%临床医生支持银屑病按需生物制剂治疗策略。
- 患者和医生均认为按需治疗可减少治疗负担并促进患者自主管理。
- 需关注复发风险、药物免疫原性及确保复发时快速获得药物。
核心结论
- 银屑病按需生物制剂治疗对患者和临床医生均可接受。
- 需正式评估临床效果和成本效益以实现该方法的真实世界潜力。
研究设计与样本
- 混合方法研究:先进行英国全国范围在线范围调查,再进行定性焦点小组。
- 调查纳入67例患者和27例临床医生;焦点小组包括15例患者和9例皮肤科医生。
主要发现
- 调查中67%(43/64)患者和78%(21/27)临床医生支持按需生物制剂治疗。
- 焦点小组中患者和医生均认为按需治疗可减少治疗负担并促进患者自主管理。
- 患者偏好受既往药物获取困难和疾病控制经历影响。
- 临床医生强调靶向选择患者、持续疾病监测和复发时快速再获取药物的重要性。
关键数值与推荐
- 调查支持率:患者67%(43/64),临床医生78%(21/27)。
- 焦点小组患者平均病程32年(范围9-64),临床医生平均皮肤科经验20年(范围8-33)。
临床怎么用
- 按需生物制剂治疗可作为减少长期治疗负担的策略,但需确保患者复发时能快速获得药物。
- 临床医生应靶向选择患者并持续监测疾病活动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic therapies have led to increasing numbers of patients with psoriasis who have clear or nearly clear skin. It is current practice to continue biologic therapy indefinitely in these patients, which contributes to a substantial long-term drug and healthcare burden. 'As needed' biologic therapy in psoriasis may address this; however, our understanding of patient and clinician perceptions of this strategy is limited. OBJECTIVES: The aim of this mixed-methods study was to gain insight into the perspectives of both patients and clinicians regarding the acceptability of an 'as needed' approach to biologic therapy in psoriasis, including potential barriers and enablers to implementation in routine care. METHODS: We first conducted UK-wide online scoping surveys of patients with psoriasis and dermatology clinicians to explore their views on 'as needed' biologic therapy. Using topic guides informed by these survey findings, we then carried out qualitative focus groups with patients and clinicians. Themes were identified using reflexive thematic analysis. RESULTS: Of 67 patients and 27 clinicians completing the scoping surveys, 67% (43 of 64 patients) and 78% (21 of 27 clinicians) supported the use of 'as needed' biologic therapy, respectively. Respondents highlighted advantages such as a reduction in healthcare burden and greater ownership of care. Challenges included logistics of 'as needed' drug provision and potential risks of disease flare and drug immunogenicity. Focus groups comprised 15 patients with psoriasis [9 female patients (60%), average disease duration 32 years (range 9-64)] and 9 dermatology clinicians [8 female clinicians (89%), average dermatology experience 20 years (range 8-33)]. Both patients and clinicians felt that an 'as needed' treatment approach will deliver a reduction in treatment burden and present an opportunity for patient-led ownership of care. Both groups highlighted the importance of ensuring ongoing access to medication and discussing the potential impact of psoriasis recurrence. Patient preferences were influenced by their lived experiences, particularly previous difficulties with medication delivery logistics and establishing disease control. Clinician perspectives were informed by personal experience of their patients adapting their own dosing schedules. Clinicians highlighted the importance of targeted patient selection for an 'as needed' approach, ongoing disease monitoring, and prompt reaccess to medications upon psoriasis recurrence. CONCLUSIONS: These data indicate that 'as needed' biologic therapy in psoriasis is acceptable for both patients and clinicians. Formal assessment of clinical effectiveness and cost-effectiveness is warranted to enable the real-world potential of this approach to be realized. Psoriasis is a common skin disease that affects up to 2% of adults in the UK and causes red, scaly patches of skin. A new group of injectable medicines (called biologics) are extremely effective at controlling psoriasis. However, continuous use of these medicines can increase the risk of negative side-effects (such as infections). ‘As needed’ biologic therapy is when a person takes their biologic medication at the first sign of psoriasis recurrence (rather than continuously). This approach has potential to reduce the risks associated with taking biologics, while still maintaining good control of psoriasis symptoms. ‘As needed’ therapy has not been used in psoriasis yet, and so we wanted to know what people with psoriasis and healthcare professionals thought about this approach. We carried out national surveys of people with psoriasis and healthcare professionals to explore their views on ‘as needed’ biologic therapy. We also held group interviews to understand in more detail the positive aspects and potential issues with this approach. Overall, we found that an ‘as needed’ approach was viewed as acceptable by people with psoriasis and healthcare professionals. They thought this approach would reduce the negative impacts of treatment and allow patients to have more ownership of their care. Potential issues included the possibility of patients’ psoriasis returning, as well as ensuring that they had access to medication quickly enough when needed. These findings indicate that ‘as needed’ biologic therapy in psoriasis is acceptable from both a patient and clinician perspective.
引用
- Gleeson D, Naveed M, Moorhead L, et al. Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study. Br J Dermatol. 2024. PMID: 38366988. doi:10.1093/bjd/ljae068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。